February 04, 2021

Synthetic Bryostatin Available to Expand Neurodegenerative Indication Trials

December 02, 2020

Neurotrope and Metuchen Pharmaceuticals Announce Completion of Merger Forming Petros Pharmaceuticals

November 20, 2020

Neurotrope, Inc. Approves Spin-Off of Neurotrope Bioscience, Inc. and Sets Record and Distribution Dates

October 06, 2020

Neurotrope Announces First Patient Dosed in Long-Term Clinical Trial of Bryostatin in Alzheimer's Disease

September 30, 2020

Neurotrope Shareholders to Own 49 Percent of Petros Under Revised Merger Agreement with Metuchen

July 30, 2020

Neurotrope Bioscience Announces Agreement with Worldwide Clinical Trials, to Conduct Ongoing Phase 2 Study of Bryostatin-1, Partially Funded by NIH, for Alzheimer's Disease

June 10, 2020

Neurotrope Announces Strategic Partnership with BryoLogyx for Supply of Synthetic Bryostatin-1 and Continuation of the National Cancer Institute (NCI) Trial for Childhood Leukemia

May 28, 2020

Neurotrope Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease

May 26, 2020

Neurotrope Announces Investor Update Conference Call

May 18, 2020

Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company

January 22, 2020

Neurotrope, Inc. Announces $18 Million Registered Direct Offering

January 22, 2020

Neurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis for Advanced Alzheimer's Disease Trial

October 08, 2019

Neurotrope Announces Review of Strategic Alternatives to Maximize Shareholder Value

September 09, 2019

Neurotrope Announces Top-line Results From Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease

August 13, 2019

Neurotrope Announces Publication Highlighting the Potential of Bryostatin as a Unique Neurorestorative Therapy

August 05, 2019

Neurotrope Announces Corporate Update and Reports Second Quarter 2019 Financial Results

July 17, 2019

Neurotrope Strategic Advisory Board Members Participating in Key Opinion Leader Call Sponsored by Oppenheimer's Biotechnology Team

July 15, 2019

Neurotrope Concludes Data Collection in Confirmatory Phase 2 Clinical Trial of Moderately Severe to Severe Alzheimer's Disease

July 11, 2019

Neurotrope to Present at the Alzheimer's Association International Conference; Neurotrope President and Chief Scientific Officer, Dr. Daniel L. Alkon, to Receive Cure Coin Award; Design of Confirmatory Phase 2 Trial to be Presented

June 24, 2019

Neurotrope CEO to Present at the Maxim Group Key Opinion Leader Discussion on Alzheimer's Disease on June 26th, 2019

June 03, 2019

Neurotrope's President and Chief Scientific Officer to Present at the Alzheimer's Solutions Conference at The University of the Sciences in Philadelphia, PA on June 3rd, 2019

May 30, 2019

Neurotrope to Present at the LD Micro 9th Annual Invitational Conference on June 4, 2019